Absorption, Metabolism, and Disposition of [14C]SDZ ENA 713, an Acetylcholinesterase Inhibitor, in Minipigs Following Oral, Intravenous, and Dermal Administration

被引：0

作者：

Francis L. S. Tse

Robert Laplanche

机构：

[1] Novartis Pharmaceuticals Corporation,Department of Drug Metabolism and Pharmacokinetics, Preclinical Safety

[2] Preclinical Safety,Department of Drug Metabolism and Pharmacokinetics

[3] Novartis Pharma Inc.,undefined

来源：

Pharmaceutical Research | 1998年 / 15卷

关键词：

Alzheimer's disease; rivastigmine; minipig; transdermal absorption; bioavailability; skin abrasion;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Purpose. SDZ ENA 713 (rivastigmine) is an acetylcholinesterase inhibitor intended for therapeutic use in Alzheimer's disease. The present study compared the pharmacokinetics of [14C]SDZ ENA 713 after intravenous, oral, and dermal administration to male minipigs, and also examined the effects of dose level and skin abrasion on transdermal absorption.

引用

页码：1614 / 1620

页数：6

共 50 条

[41] Biotransformation of [14C]-phenylbutazone after oral or intravenous administration to cattle.
Smith, D
Huwe, JK
Lorentzsen, M
Harrington, GE
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U103 - U103
[42] Pharmacokinetics of [14C]Ciclesonide After Oral and Intravenous Administration to Healthy Subjects
Ruediger Nave
Thomas D. Bethke
Sjoerd P. van Marle
Karl Zech
[J]. Clinical Pharmacokinetics, 2004, 43 : 479 - 486
[43] Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects
Nave, R
Bethke, TD
van Marle, SP
Zech, K
[J]. CLINICAL PHARMACOKINETICS, 2004, 43 (07) : 479 - 486
[44] Metabolism of the taxane analog [14C]BMS-275183 following oral administration to rats and dogs
Ly, Van T.
Comezoglu, Nigun
Zhang, Donglu
Humphreys, W. Griffith
Ekhato, Ihoezo V.
[J]. DRUG METABOLISM REVIEWS, 2006, 38 : 178 - 178
[45] Mass balance and metabolism of aclidinium bromide following intravenous administration of [14C]-aclidinium bromide in healthy subjects
Ortiz, Stephan
Flach, Stephen
Ho, John
Li, Fanying
Caracta, Cynthia F.
Garcia Gil, Esther
Jansat, Josep M.
[J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (01) : 39 - 45
[46] Absorption, Metabolism, and Excretion of [14C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity
Nicolas, Olivier
Moliner, Patricia
Soubayrol, Patrick
Vitse, Olivier
Roy, Sebastien
Cabanis, Marie-Jose
Turner, Tim
Klieber, Sylvie
Muccio, Stephane
Arabeyre, Catherine
Brun, Priscilla
[J]. CLINICAL DRUG INVESTIGATION, 2023, 43 (08) : 653 - 665
[47] Absorption, Metabolism, and Excretion of [14C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity
Olivier Nicolas
Patricia Moliner
Patrick Soubayrol
Olivier Vitse
Sebastien Roy
Marie-José Cabanis
Tim Turner
Sylvie Klieber
Stephane Muccio
Catherine Arabeyre
Priscilla Brun
[J]. Clinical Drug Investigation, 2023, 43 : 653 - 665
[48] Disposition and metabolic profile in monkey liver following single and multiple oral dosing of [14C]ribavirin and [14C]viramidine.
Yeh, LT
Lourenco, D
Lin, CC
[J]. HEPATOLOGY, 2003, 38 (04) : 746A - 746A
[49] Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics
Cassidy, Kenneth C.
Gueorguieva, Ivelina
Miles, Colin
Rehmel, Jessica
Yi, Ping
Ehlhardt, William J.
[J]. XENOBIOTICA, 2018, 48 (04) : 382 - 399
[50] Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration
Sufeng Zhou
Wei Liu
Chen Zhou
Lingling Zhang
Lijun Xie
Zhaoqiang Xu
Lu Wang
Yuqing Zhao
Lian Guo
Juan Chen
Lieming Ding
Li Mao
Yi Tao
Chen Zhang
Sijia Ding
Feng Shao
[J]. Cancer Chemotherapy and Pharmacology, 2020, 86 : 719 - 730

← 1 2 3 4 5 →